Product References
A Biosensor for the Mitotic Kinase MPS1 Reveals Spatiotemporal Activity Dynamics and Regulation.
Current biology : CB
Kuijt TEF,Lambers MLA,Weterings S,Ponsioen B,Bolhaqueiro ACF,Staijen DHM,Kops GJPL
44-1325G was used in Immunocytochemistry to develop MPS1sen, a sensitive and specific FRET-based biosensor for MPS1 activity o understand when and where MPS1 activation occurs and how MPS1 signaling is modulated during mitosis.
Mon Oct 05 00:00:00 UTC 2020
Checkpoint signaling and error correction require regulation of the MPS1 T-loop by PP2A-B56.
The Journal of cell biology
Hayward D,Bancroft J,Mangat D,Alfonso-Pérez T,Dugdale S,McCarthy J,Barr FA,Gruneberg U
44-1325G was used in Immunocytochemistry-immunoflourescence to investigate if the BUBR1-bound pool of PP2A-B56 regulates monopolar spindle 1 T-loop autophosphorylation and hence its activation status in mammalian cells.
Mon Oct 07 00:00:00 UTC 2019
Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy.
British journal of cancer
Faisal A,Mak GWY,Gurden MD,Xavier CPR,Anderhub SJ,Innocenti P,Westwood IM,Naud S,Hayes A,Box G,Valenti MR,De Haven Brandon AK,O'Fee L,Schmitt J,Woodward HL,Burke R,vanMontfort RLM,Blagg J,Raynaud FI,Eccles SA,Hoelder S,Linardopoulos S
Published figure using Phospho-TTK (Thr33, Ser37) polyclonal antibody (Product # 44-1325G) in Immunoprecipitation
Tue Apr 25 00:00:00 UTC 2017
Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
Cancer research
Gurden MD,Westwood IM,Faisal A,Naud S,Cheung KM,McAndrew C,Wood A,Schmitt J,Boxall K,Mak G,Workman P,Burke R,Hoelder S,Blagg J,Van Montfort RL,Linardopoulos S
44-1325G was used in immunocytochemistry to identify mutations in the kinase domain of MPS1 that confer resistance against multiple inhibitors.
Sat Aug 15 00:00:00 UTC 2015
Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
PloS one
Martinez R,Blasina A,Hallin JF,Hu W,Rymer I,Fan J,Hoffman RL,Murphy S,Marx M,Yanochko G,Trajkovic D,Dinh D,Timofeevski S,Zhu Z,Sun P,Lappin PB,Murray BW
44-1325G was used in immunocytochemistry to assess Mps1 kinase inhibitors as cancer treatments.
Tue Jun 14 00:00:00 UTC 2016
Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1).
Journal of medicinal chemistry
Naud S,Westwood IM,Faisal A,Sheldrake P,Bavetsias V,Atrash B,Cheung KM,Liu M,Hayes A,Schmitt J,Wood A,Choi V,Boxall K,Mak G,Gurden M,Valenti M,de Haven Brandon A,Henley A,Baker R,McAndrew C,Matijssen B,Burke R,Hoelder S,Eccles SA,Raynaud FI,Linardopoulos S,van Montfort RL,Blagg J
Fri Dec 27 00:00:00 UTC 2013
Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1).
Journal of medicinal chemistry
Naud S,Westwood IM,Faisal A,Sheldrake P,Bavetsias V,Atrash B,Cheung KM,Liu M,Hayes A,Schmitt J,Wood A,Choi V,Boxall K,Mak G,Gurden M,Valenti M,de Haven Brandon A,Henley A,Baker R,McAndrew C,Matijssen B,Burke R,Hoelder S,Eccles SA,Raynaud FI,Linardopoulos S,van Montfort RL,Blagg J
Fri Dec 27 00:00:00 UTC 2013
Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1).
Journal of medicinal chemistry
Naud S,Westwood IM,Faisal A,Sheldrake P,Bavetsias V,Atrash B,Cheung KM,Liu M,Hayes A,Schmitt J,Wood A,Choi V,Boxall K,Mak G,Gurden M,Valenti M,de Haven Brandon A,Henley A,Baker R,McAndrew C,Matijssen B,Burke R,Hoelder S,Eccles SA,Raynaud FI,Linardopoulos S,van Montfort RL,Blagg J
Fri Dec 27 00:00:00 UTC 2013